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treatment for early breast cancer are invited to receive routine annual
mammography. There is no randomized controlled trial evidence to
support this schedule, and model-based analysis is required. This
paper describes a novel data collection and model calibration process
to analyze the cost-effectiveness of alternative follow-up schedules
for early breast cancer survivors. Methods: A discrete event simula-
tion model describes the progression of early breast cancer after the
completion of primary treatment, representing impalpable and pal-
pable recurrence and the detection of impalpable disease via follow-
up mammography. Retrospective data from the South Australian
Cancer Registry and clinical and administrative hospital databases
were linked for 407 postmenopausal women diagnosed with
moderate-prognosis early breast cancer from 2000 to 2008. These data
formed the basis of a patient-level probabilistic calibration process.ee front matter Copyright & 2014, International S
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e, SA 5005, Australia.Results: For 50- to 69-year-old survivors, annual follow-up for 5 years,
with visits every 2 years thereafter, appears to be cost-effective. For
women aged 70 to 79 years at diagnosis, a surveillance schedule
similar to general population screening (2 yearly) appears to be most
cost-effective if high rates of adherence can be maintained. Conclu-
sions: This study demonstrated the potential value of combining
linked, retrospective data and decision analytic modeling to provide
estimates of costs and health outcomes that are sufﬁciently robust to
inform cancer clinical guidelines and individual patient decisions
regarding appropriate follow-up schedules.
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Breast cancer is the most common incident form of malignancy
in Australian women, accounting for 28% of cancer diagnoses in
2008 [1]. Between the periods 1982-1987 and 2006-2010, in
Australia the 5-year relative survival rate from breast cancer
increased from 72% to 89% [1]. The largest survival gain was for
women aged between 50 and 69 years. The 5-year relative
survival rate increased from 70% to 91% for women aged 50 to
59 years and from 72% to 93% for women aged 60 to 69 years [1].
Given the aging population, the number of women diagnosed
with breast cancer is expected to increase [1], and with improving
survival, there is a growing population of breast cancer survivors
who will all require mammographic follow-up during their life-
time [2]. Women with a history of breast cancer are at an
increased risk of cancer within the breast (either recurrence or
a new primary), but it is unclear how often, or for how long, we
should continue to perform mammography in women who are
disease free following primary treatment for early breast cancer
[3]. Mammographic follow-up is effectively screening of a high-
risk population. Not all women who have survived early breastcancer, however, have the same risk of breast cancer recurrence
or a second primary, with rates per 1000 woman-years varying by
patient, tumor, and treatment characteristics at initial diagnosis
[4].
Many international guidelines exist, and all acknowledge the
paucity of deﬁnitive evidence on follow-up care after breast
cancer [5], with much of the information coming from low-level
observational studies [5]. There is no randomized controlled trial
(RCT) evidence on which to base guideline recommendations of
annual compared with other frequency of follow-up mammog-
raphy, and there is currently no tailoring of mammographic
frequency according to risk [3,5–9]. In a recent guideline update,
no primary studies were identiﬁed that addressed how long
follow-up should continue after diagnosis or treatment [5].
Although RCTs can provide an unconfounded estimate of
effect, and are a common and relatively easy source for effective-
ness and cost data, they are limited to the patients, interventions,
and time span of the trial and are sometimes not feasible.
Potential barriers to performing RCTs in follow-up for cancer
include difﬁculty with patient accrual [10] (e.g., if patients have a
50% chance of receiving follow-up that is less frequent thanociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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to be in a trial) and the large sample size and long follow-up (and
thus cost implications) required to demonstrate a signiﬁcant
difference (or non inferiority) between alternative follow-up
programs for different patient subgroups [10]. Reviews of the
many observational studies that have investigated the clinical
(but not economic) effects of mammographic surveillance have
shown these studies to be of poor quality and prone to bias,
particularly length bias [11]. As such, observational studies
provide a limited basis for the direct, nonmodeled evaluation of
cost-effectiveness of alternative surveillance strategies.
To move away from a “one-size-ﬁts-all” mammographic
follow-up schedule to a “personalized” mammographic schedule
based on the risk of recurrence, given that RCTs are unlikely to
occur, we need to consider alternative research methodologies to
guide clinical practice.
Decision analytic modeling facilitates data synthesis to
describe disease progression over an extended time horizon to
capture all important differences in costs and beneﬁts between
alternative strategies. Most models used to evaluate surveillance
options include unobservable input parameters. In the case of
cancer follow-up, we cannot observe the time at which patients
develop asymptomatic recurrence. Calibration is often used to ﬁt
values for these parameters, such that models’ outputs match
some observed data for the population being evaluated [12]. This
process is most common in models of population-based screen-
ing programs [13], though previous models have not used
patient-level data to represent observed surveillance pathways
to inform the calibration of the underlying disease progression
parameters. The use of longitudinal data that include patient-
level surveillance pathways and outcomes may provide a more
robust basis for calibrating surveillance models.
Discrete evaluation simulation (DES) has been used to eval-
uate a wide range of screening and other surveillance activities
[14–19]. For health technology assessment, DES is most com-
monly used to facilitate the representation of complex model
structures [20], which is often the case for surveillance models
that represent the full disease course from incidence to death. In
the context of calibrating surveillance models, however, the
individual-level nature of DES may confer other advantages over
the more commonly used cohort-based state transition model.
Such individual-level models allow observed individual surveil-
lance pathways to be speciﬁed as input parameters, which
extracts greater value from individual-level data, where available.
This article describes the development, calibration, and cost-
effectiveness analyses of an early breast cancer surveillance DES
model. The DES model was used to analyze three alternative
mammographic follow-up schedules for postmenopausal women
who were disease free following primary treatment for moderate-
prognosis early breast cancer, taking into account age and
adherence to mammography.Methods
Model Structure
The model represented disease pathways related to early breast
cancer. DES was selected because the model was calibrated to
individual-level patient data [21]. Patients move through the
model and experience events at any discrete time period after
the previous event. For any given patient, the pathway may be
inﬂuenced by the individual characteristics (e.g., age and meno-
pausal status), the tumor (e.g., size, nodal status, and grade), or
the treatment, which, in turn, has an impact on health service
costs, quality of life, and overall survival.The DES model was developed in Simul8 (Fig. 1). The model
uses the following health states to represent progression of
breast cancer in women who are disease free after the comple-
tion of primary treatment (surgery, radiotherapy, chemotherapy): Disease free—no recurrence of breast cancer.
 Impalpable local recurrence—relapse within the treated or
opposite breast that is detectable only by follow-up
mammography. Palpable local recurrence—relapse within the treated or oppo-
site breast that is clinically detectable by a doctor or the
patient. Removed impalpable local recurrence—local recurrence
detected by follow-up mammography and surgically removed
(adjuvant treatment), rendering the patient disease free. Distant metastases—disease relapse outside the breast/axilla.
 Breast cancer death—death due to breast cancer.
 Other-cause death—death not caused by breast cancer.
Mammographic follow-up is represented as an instantaneous
event. Model assumptions are presented in Table 1. The following
section describes the rationale for the pathways between the
represented events.
Model Pathways
Women enter the model disease free, but are at risk of developing
a recurrence. A woman will leave the disease-free state if she
develops a local recurrence. Initially, this will be impalpable, and
detectable only via mammographic surveillance. If an impalpable
local recurrence is not detected, and the patient does not die in
the intervening period, the recurrent tumor will either continue
to grow locally and be detected clinically by the doctor or the
patient (palpable local recurrence) or metastasize to other parts
of the body (distant metastases).
Women can develop distant metastases from any health
state, which is typically incurable, and such women are assumed
to die of causes related to breast cancer (breast cancer death).
Before the development of distant metastases, women can die
from causes unrelated to breast cancer at any time (other-cause
death).
For women with an impalpable local recurrence, a true
positive follow-up mammogram results in the removal of the
lesion (removed impalpable local recurrence). Following a false-
negative follow-up mammogram, the lesion will remain undiag-
nosed and continue to grow. For women in the disease-free state,
a false-positive follow-up mammogram results in a biopsy and
upon a negative result, such women return to the disease-
free state.
Model Scenarios
The DES model was used to analyze three alternative mammo-
graphic follow-up schedules for postmenopausal women who
were disease free following primary treatment for moderate-
prognosis early breast cancer, taking into account age at diag-
nosis and adherence with mammography. The 12 scenarios are
described in Table 2.
The age cohorts were 50 to 69 years and 70 to 79 years, to
reﬂect the current target age group for breast cancer screening in
Australia and an older target age group, respectively.
Mammographic schedules were chosen to reﬂect the current
annual follow-up interval and two less intense schedules that
were deemed feasible options within Australia as informed by
expert consultation. The least intensive option was 2-year mam-
mography (one surveillance episode every 2 years), which is the
frequency currently recommended for population-based screen-
ing. A “mixed” schedule consisted of annual mammography for
Follow-up 
mammography
Removed 
impalpable local 
recurrence
Impalpable local 
recurrence
Distant 
metastases
Palpable local 
recurrence
Disease free
Other cause 
death
Breast  cancer 
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Completion of 
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Fig. 1 – Structure of Discrete Event Simulation model describing the possible progression of early breast cancer after the
completion of treatment, and the detection of impalpable disease by follow-up mammography.
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reﬂect a follow-up frequency intermediate between annual and
2-year surveillance. A “no surveillance” option was not consid-
ered to be clinically safe or efﬁcient for women who have a
personal history of breast cancer. This differs from early stage
melanoma, for example, in which most of the recurrences are
detected by the patient and “no follow-up” is currently being
assessed as a viable option.
In the absence of South Australian or national data describing
adherence with follow-up mammography by women with a
personal history of breast cancer, we assumed adherence would
be higher than with screening mammography of asymptomatic
women with no personal history of breast cancer. In 2009-2010 in
Australia, 55% of eligible women attended Breast Screen Australia
[22]. We separately modeled 75% and 90% adherence probabil-
ities, applied to each follow-up mammography encounter, to
provide feasible lower and upper boundaries of mammographic
attendance by Australian breast cancer survivors.Table 1 – Model assumptions.
1. All patients are women.
2. Women aged Z50 y are deﬁned as postmenopausal.
3. Local recurrence refers to the recurrence of breast cancer in the
treated breast/axilla or new primary breast cancer in the
contralateral breast.
4. A local recurrence is curable, and women with local recurrence
will not experience a breast cancer death unless they develop
metastatic disease.
5. A local recurrence will be initially impalpable and if untreated
will continue to increase in size and eventually become palpable.
6. Early detection of a local recurrence when impalpable reduces
the risk of metastatic disease compared with late detection of a
local recurrence when palpable.
7. Once a local recurrence (impalpable or palpable) is detected, it
will be surgically removed (adjuvant treatment) rendering the
patient disease free.
8. Distant metastases include all systemic relapses outside the
breast/axilla, and include supraclavicular lymphadenopathy as
well as visceral metastases in lung, liver, bone, brain, and
other sites.
9. Women are at risk of developing distant metastases with or
without the prior development of local recurrence.
10. Distant metastases are incurable and result in death from breast
cancer.Model Inputs
Data on breast cancer follow-up and recurrence are not routinely
collected in South Australia. Because no single data source within
South Australia contained the information required, we obtained
ethics approval from SA Health Human Research Ethics Commit-
tee to extract and link data across the South Australian Cancer
Registry, public metropolitan hospital database (Open Architec-
ture Clinical Information System), statewide inpatient database
(Integrated South Australian Activity Collection, which contains
administrative data on both public and private hospitals), and the
Registry of Births, Deaths, and Marriages.
We constructed a patient-level data set of women with early
breast cancer and stratiﬁed women according to prognosis on the
basis of pathological criteria that were routinely collected in
South Australia. For each woman we determined the follow-up
she received and her disease course. This included the frequency
of her mammographic follow-up, whether she developed a
recurrence (and if so, whether in the breast or distant, and when
it was detected), and whether she died from breast cancer.
Eleven hundred postmenopausal women diagnosed with
early breast cancer between 2000 and 2008, who had their
primary breast cancer treatment and mammographic follow-up
in the public health system, were identiﬁed and followed until
June 30, 2011. The original treatment for all women included
surgery  radiotherapy  chemotherapy. For each woman, we
collected data on date of birth, date of surgery, tumor size, nodal
status and grade of the primary breast cancer, date and type ofTable 2 – Model scenarios for moderate subgroup.
Mammography schedules Adherence (%)
50–69 y old
2 y 90
Mixed 90
Annual 90
2 y 75
Mixed 75
Annual 75
70–79 y old
2 y 90
Mixed 90
Annual 90
2 y 75
Mixed 75
Annual 75
Table 3 – Observed outcomes of postmenopausal women with moderate prognosis breast cancer in South
Australia (n ¼ 407).
Event Time
horizon
Total
event rate
Patient-years
at risk
Incidence
rate
SD Lower
95% CI
Upper
95% CI
Local recurrence 5 y 19 1768 0.011 0.002 0.006 0.016
10 y 24 2407 0.010 0.002 0.006 0.014
Breast cancer death 5 y 17 1802.5 0.009 0.002 0.006 0.014
10 y 28 2483 0.011 0.002 0.008 0.016
Other-cause death 5 y 9 1802.5 0.005 0.002 0.002 0.009
10 y 25 2483 0.010 0.002 0.007 0.014
CI, conﬁdence interval.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 6 9 – 6 7 8672ﬁrst recurrence, date and cause of death, and date and result of
each follow-up mammogram. From these data, we calculated the
age and menopausal status at diagnosis and the Nottingham
Prognostic Index (NPI) for the primary breast cancer [23]. The NPI
is calculated as follows:
NPI ¼ Tumorsize cmð Þ  0:2 þ Lymph node stage 1,2,3ð Þ þ
Histologic grade 1,2,3ð Þ
Prognosis can be deﬁned in terms of the NPI score. Tumors with
excellent prognosis have an NPI score o/= 2.4, tumors with a
good prognosis have a score o/= 3.4, tumors with moderate
prognosis have a score 43.4 and o/= 5.4, and tumors with poor
prognosis have a score 45.4. The model calibration process and
results are reported for the largest subgroup of our study cohort,
the postmenopausal (age Z50 years) moderate-prognosis group
(n ¼ 407) (Table 3).
Contemporary Australia cost (AU $2011) data were identiﬁed
from the literature (Table 4) [24]. Verry et al. [24] used decision
analysis to estimate the effectiveness and cost-effectiveness of
sentinel lymph node biopsy compared with axillary node dis-
section in patients with early-stage breast cancer. The authors
provided annual cost data separately for follow-up (history and
examination  2, annual mammography), local recurrence, axil-
lary recurrence, distant metastases, and end-of-life costs. For ourTable 4 – Base-case, best-case, and worst-case weekly co
the model.
Health states Base-case values Best-case va
Weekly
costs ($)†
Utilities Weekly
costs ($)†
Disease-free† 3.2 0.832 2.4
Surveillance‡ 89.50 0.01 89.50
ILR 3.2 0.832 2.4
RILR—surgery
costs
188.5 0.655 141.4
RILR—ongoing
costs
3.2 0.752 2.4
PLR—surgery
costs
188.5 0.655 235.7
PLR—ongoing
costs
3.2 0.752 2.4
Distant
metastases
638.7 0.443 798.4
ILR, impalpable local recurrence; PLR, palpable local recurrence; RILR, re
* Best case from the perspective of increased surveillance frequency.
† Disease-free ¼ costs of history and examination  2 (i.e., two clinic vis
‡ Surveillance ¼ costs of single mammogram encounter.“disease-free” state, we used the costs pertaining to the two clinic
visits per year (history and examination  2), and for “surveil-
lance,” the costs of a single mammography encounter. For costs
pertaining to the health state “removed impalpable local recur-
rence year 1,” we used the weighted costs of the annual
probabilities of local recurrence in the treated breast as ﬁrst
event and of axillary recurrence as the ﬁrst event. We assumed
that the costs of “palpable local recurrence year 1” were identical
to those of “removed impalpable local recurrence year 1.” We
assumed that the costs of “impalpable local recurrence,”
“removed impalpable local recurrence year 2þ,” and “palpable
local recurrence year 2þ” were identical to those of the “disease-
free” health state. To derive a single cost for distant metastases,
we summed the total costs of distant metastases with total end-
of-life costs and divided this by an estimated mean survival with
distant metastases of 3 years. All mean costs were then con-
verted from annual to weekly costs. Upper and lower cost values
were calculated by adding or subtracting 25% from the base-case
weekly costs.
Utility weights for the model health states were derived
from a pooled regression-based analysis of reported utility
weights for health states relating to breast cancer (Table 4)
[25]. Derived utility weights were based on patients’ valuing
their own health using the EuroQol ﬁve-dimensionalsts, in AU $2011, and utilities for health states in
lues* Worst-case values* References
Utilities Weekly
costs ($)†
Utilities Costs Utilities
0.832 4.0 0.832 [24] [25,26]
0 89.50 0.02 [24] [27]
0.832 4.0 0.832 [24] [26]
0.794 141.4 0.655 [24] [26]
0.832 4.0 0.752 [24] [25]
0.655 141.4 0.655 [24] [26]
0.752 4.0 0.752 [24] [25]
0.443 479.0 0.655 [24] [26]
moved impalpable local recurrence.
its).
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of surgery and nonsurgical treatment and differentiate
between ﬁrst and subsequent years postdiagnosis. For the
metastatic health state, the values reﬂect treatment type (non-
speciﬁed) and response (nonspeciﬁed) to treatment. A quality-
of-life decrement associated with mammography screening
was identiﬁed in Tengs and Wallace [26], based on work by
de Koning et al. [27].
Other-cause death was calculated by subtracting the propor-
tion of Australian women who died from breast cancer from age-
speciﬁc mortality rates derived from Australian life-tables [28–
29].
Model Calibration
Probabilistic model calibration was performed according to the
seven-step approach described by Vanni et al. [12], which inte-
grates model calibration with probabilistic sensitivity analysis:1. Selection of calibration targets—Calibration targets were
selected for the 407 women for whom a linked data set had
been compiled. Five- and 10-year incidence rates (with lower
and upper 95% conﬁdence limits) were sought for recurrence
within the breast (breast recurrence), distant metastases,
breast cancer death, and other-cause death. Breast recur-
rences were identiﬁed from pathology and mammography
data available for all women. Mortality data, including cause
of death, were extracted from South Australian Cancer Regis-
try. On review, other-cause death was discarded as a calibra-
tion target because of the small numbers of observed events.
Distant metastases incidence was sought from available
inpatient data, though these data were deemed insufﬁcient
to reliably identify distant metastases, and so this calibration
target was also discarded.2. Input parameters included in the calibration process—All
disease progression input parameters plus the test character-
istics of the mammography were calibrated. To reduce the
parameter space to be searched, prior probability functions
were speciﬁed for these parameters. Beta distributions were
used to represent reported values for the sensitivity and
speciﬁcity of mammography [30]. For the time to event
parameters, Weibull distributions were speciﬁed to facilitate
time-varying event rates. Uniform ranges for the alpha and
beta parameters for each Weibull function were speciﬁed to
represent the uncertainty around the event rates reported in
the following data sources:
a. Ten-year event rates for disease progression from the
disease-free state to impalpable local recurrence and from
disease-free to distant metastases were extracted from the
Early Breast Cancer Trialists’ Collaborative Group [31].
b. One-year event rates for disease progression from impal-
pable to palpable local recurrence, and from impalpable
local recurrence, palpable local recurrence, and removed
impalpable local recurrence, respectively, to distant meta-
stases, were based on expert consultation.
c. One-year event rates for progression from distant meta-
stases to breast cancer death were derived for published
modeled evaluations of systemic treatments for early
breast cancer [32].3. Convergence criteria—Convergence describes the identiﬁca-
tion of sets of input parameter values that predict the
observed model output parameter values with sufﬁcient
accuracy. Sampled input parameter sets were deﬁned as
convergent if all output parameters lay within the 95% con-
ﬁdence intervals for the observed value for every calibration
target (5-year and 10-year event rates for both in-breast
recurrence and breast cancer death).4. Parameter search strategy—A random search strategy was
used to sample sets of input parameter values from the
deﬁned probability functions. Each sampled set was used to
populate the model, and the associated predictions of the
calibration targets were compared with the observed values to
determine convergence.5. Stopping rule—We repeated steps 3 and 4 until we had at least
1000 convergent sets of input parameter. Testing conﬁrmed
nonsigniﬁcant variation in the mean output values across
1000 and 2000 convergent parameter sets.6. Goodness-of-ﬁt measures—To represent the relative accuracy
of the alternative convergent sets of input parameter values
with respect to the observed calibration targets, we used the
chi-squared goodness-of-ﬁt method. This measure reﬂects the
uncertainty around the observed calibration targets [12] and
has been found to be more sensitive than other measures to
variations in model accuracy [33].7. Integrating the results of the calibration and model sensitivity
analysis—The inverse of the chi-square statistic (which incor-
porates the standard error of the observed data for the
calibration targets) was used to assign probability weights to
each convergent input parameter set, which informed the
likelihood of each set being sampled during a probabilistic
sensitivity analysis [34]. The cost input parameters were not
included in the probabilistic analysis because the scenarios
tested in the deterministic analysis were extreme and more
realistic ranges had very little impact on the model outputs.
Model Analysis
The model was run for the same 2000 sampled sets of convergent
input parameter values for each scenario. Model outputs were
total costs (health state costs þ costs of surveillance) and total
quality-adjusted life-years (QALYs) across the model health
states. Within each age and adherence group (e.g., 50–69-year-
olds assuming 75% adherence), mean incremental cost-
effectiveness ratios (ICERs) were estimated between mammo-
graphic schedules arranged in increasing order of effectiveness.
Estimates of the probability of each follow-up scenario max-
imizing net beneﬁts were also generated for a range of QALY
threshold values for each age and adherence group.
Best-case and worst-case scenario analyses were deﬁned with
respect to the cost-effectiveness of more frequent surveillance.
The best-case scenario was applied to the 50- to 69-year-old
cohort, assuming 90% adherence. Compared with the base case,
higher weekly costs for removed palpable local recurrence in the
ﬁrst year ($235.70) and for distant metastases ($798.40), lower
weekly costs for all other health states, and higher utility values
for removed impalpable recurrence in the ﬁrst (0.794) and
following years (0.832) were used. The worst-case scenario was
applied to the 70- to 79-year-old cohort, assuming 75% adher-
ence. Higher weekly costs for disease-free, impalpable local
recurrence, removed impalpable local recurrence for year 2þ,
and palpable local recurrence for year 2þ ($4.00), lower weekly
costs for all other health states, and higher utility values for
distant metastases (0.655) were used.
In the base case, the applied QALY decrement associated with
follow-up mammography of 0.01 is equivalent to a 0.5 utility
decrement for 1 week, or a 0.25 utility decrement for 2 weeks,
reﬂecting the heightened anxiety around the surveillance period.
The QALY decrement also captures the false-positive effect for
the small proportion of patients undergoing further investiga-
tions to rule out recurrence. For the best-case scenario, the utility
decrement for surveillance was decreased to zero, and in the
worst-case scenario, the utility decrement for surveillance was
increased (0.02).
Table 5 – Mean incremental cost-effectiveness results for postmenopausal women with moderate-prognosis
early breast cancer.*
Mammography
schedules
Adherence
(%)
Breast cancer deaths
(%)
Mean costs
($)
QALY difference (with
decrement)
ICER
($)
50–69 y old
2 y 90 0.331 10,553
Mixed 90 0.330 10,693 0.005 28,199
Annual 90 0.329 11,019 0.003 126,481
2 y 75 0.331 10,458
Mixed 75 0.330 10,596 0.006 21,481
Annual 75 0.329 10,852 0.002 133,525
70–79 y old
2 y 90 0.188 7,425
Mixed 90 0.188 7,567 0.002 69,608
Annual 90 0.187 7,753 0.000 413,230
2 y 75 0.189 7,360
Mixed 75 0.188 7,491 0.003 40,706
Annual 75 0.188 7,630 0.000 377,290
Note. Mixed means follow-up mammography every year for 5 y and then every 2 y; 2 y means follow-up mammography every 2 y.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* Based on the mean output values from the probabilistic analysis of the weighted sampling of the convergent sets of input parameters.
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Base-Case Analysis
Table 5 reports the results of the base-case scenarios for the
alternative mammographic follow-up schedules in women with
moderate-prognosis tumors, by age at diagnosis, adherence with
follow-up mammography, and assuming a 0.01 QALY decrement
associated with a surveillance episode. The ICERs varied by
assumed adherence levels.
Assuming 90% adherence, the cost-effectiveness of mixed
follow-up compared with that of 2-year follow-up range from
$28,199 per QALY gained for women aged 50 to 69 years to $69,608
for women aged 70 to 79 years. The corresponding values for
annual screening compared with mixed follow-up range from
$126,481 for women aged 50 to 69 years to $413,230 for women
aged 70 to 79 years.
If adherence is reduced to 75%, the cost-effectiveness of
mixed follow-up compared with that of 2-year follow-up reduces
to $21,481 per QALY gained for women aged 50 to 69 years to
$40,706 for women aged 70 to 79 years. The corresponding values
for annual screening compared with mixed follow-up range from
$133,525 for women aged 50 to 69 years to $377,290 for women
aged 70 to 79 years.
The results are sensitive to the assumed adherence rate due
to the small absolute gain in QALYs between surveillance
options, which means that changes in adherence result in larger
relative changes in QALY gains compared with cost differences.
For example, in 50- to 69-year-old women, moving from a mixed
schedule to an annual schedule results in an incremental cost
difference of $326 assuming 90% adherence, and $257 assuming
75% adherence. The corresponding QALY differences are 0.003
and 0.002.Best-Case and Worst-Case Scenario Analyses
Best-case and worst-case scenario analyses were undertaken
around the cost and utility input parameters, as presented in
Table 6. Compared with the base-case results, the best-case cost
and utility weight scenario results in substantially lower ICERs in
both analyses, primarily because of the best-case assumption oflower costs associated with the treatment of mammographically
detected local recurrence (impalpable local recurrence) compared
with the costs of treatment for local recurrence that is detected
clinically (palpable local recurrence). The worst-case scenario did
not result in any policy-relevant variation; that is, the ICER did
not move signiﬁcantly toward recognized cost-effectiveness
thresholds.
Probabilistic Sensitivity Analyses
The results of the probabilistic sensitivity analyses are shown
in Figure 2, which describes the probabilities of cost-effectiveness
for alternative follow-up schedules and adherence rates, by QALY
threshold value, for the 50- to 69-year-old (Fig 2A) and 70- to 79-
year-old cohorts (Fig 2B), respectively.
For women aged 50 to 69 years, assuming 90% adherence
there is signiﬁcant uncertainty regarding the optimal schedule.
The mixed (annual to 2-year) schedule has the highest probability
of cost-effectiveness at 40%, though the constant 2-year schedule
has a 35% probability, and thus annual surveillance has a 25%
probability. This result does not vary greatly over feasible ranges
of the threshold QALY value; for example, at a value of $25,000,
the probability of an annual schedule being cost-effective reduces
to less than 13%, but the other two schedules have probabilities
of 40% and 47%. Assuming 75% adherence, the probability of
2-year surveillance being cost-effective decreases, resulting in
increased uncertainty around the choice of the optimal schedule.
For women aged 70 to 79 years, 2-year surveillance is more
likely to be cost-effective, with a 56% and 43% probability at QALY
threshold values of $25,000 and $50,000, respectively (assuming
90% adherence). At 75% adherence, uncertainty is increased, with
both the 2-year and mixed schedules having a 37% probability of
cost-effectiveness at a $50,000 threshold value.Discussion
Based on commonly implied cost-effectiveness thresholds for
Australia [35], the reported model-based analysis of alternative
surveillance strategies following primary treatment of early
breast cancer, for moderate-prognosis women aged 50 to 69 years
at diagnosis, suggests that annual follow-up for 5 years with
2-year visits thereafter (the mixed surveillance option) is
Table 6 – Best-case and worst-case cost and utility input parameter scenario analyses.*
Mammography schedules and
adherence (%)
Best-case scenario Worst-case scenario
Cost
difference ($)
QALY
difference
ICER
($)
Cost
difference ($)
QALY
difference
ICER
($)
50–69 y, 90% adherence
Mixed MMG  2-y MMG 142 0.0094 15,070 137 0.0047 28,794
Annual MMG  mixed MMG 332 0.0078 42,567 320 0.0021 154,269
70–79 y, 75% adherence
Mixed MMG  2-y MMG 135 0.0073 18,454 127 0.0031 41,288
Annual MMG  mixed MMG 141 0.0023 61,063 137 0.0001 930,419
Note. Cost and QALY differences are presented between the ordered options; e.g., the $142 cost difference is the additional cost of the mixed
program relative to the 2-y program.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* Best case is deﬁned from the perspective of favoring more intensive surveillance; please see text for further details.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 6 9 – 6 7 8 675cost-effective. For women aged 70 to 79 years at diagnosis, a
surveillance schedule similar to general population screening
(2-year visits) appears to be most cost-effective if high rates of
adherence can be maintained; otherwise, a mixed, (annual to
2-year) schedule might be preferred.
As expected, the likelihood of annual follow-up schedules being
the most cost-effective option is positively associated with increas-
ing QALY thresholds, and decreasing adherence with mammog-
raphy (90% to 75%). In the evaluated, moderate risk subgroup, the
results suggest, it is unlikely that the incremental beneﬁts of
ongoing annual surveillance compensate for the incremental costs.
Deterministic scenario analyses identiﬁed some uncertainty
with respect to extreme assumptions around the costs of treating
mammographically and clinically detected local recurrence, and
the utility decrement associated with surveillance. A contempo-
rary Australian cost and utility study speciﬁcally designed to
inform these surveillance model parameters would improve the
robustness of the model. The model would also be improved
through the collection of more detailed individual-level data to
inform additional calibration targets (e.g., to differentiate between
mammographically and clinically detected local recurrence,
relapse within the treated or opposite breast, recurrence vs. new
primary breast cancer, etc.), as well as to reduce the uncertainty
around the observed calibration target parameter values.
A recent health technology assessment of surveillance strat-
egies for women with early breast cancer in the United Kingdom
used an alternative modeling approach.11 Using a cohort Markov
model, Robertson et al. [11] represented disease progression in
more detail, but they did not calibrate (or externally validate)
their model. Different frequencies (12-, 18-, 24-, and 36-month
intervals) and different methods of surveillance (no surveillance,
mammography, mammography þ clinical examination, mag-
netic resonance imaging þ clinical examination) were tested,
including subgroup analyses of two hypothetical women aged 40
years and 70 years, representing, respectively, higher and lower
likelihoods of relapse within the breast (based on increased risk
of recurrence, shorter time for an undetected cancer to progress
to worse risk proﬁle, and more aggressive and costly treatment of
recurrence in the younger woman). Their results suggested that
more intensive follow-up of women judged to be at high risk, and
less intensive follow-up of women judged to be at low risk, may
be cost-effective [11]. This is consistent with ﬁndings reported in
this article, which reports results for a moderate risk group.
The ISPOR Task Force on Good Research Practices in Modeling
Studies states that model validation is a key requirement for
high-quality models [36]. We followed a recently published
reporting framework for evaluating model performance (valida-
tion and calibration) suggested by Haji Ali Afzali et al. [37]. Expertopinion was obtained to ensure that model, data sources, and
results made intuitive sense; code within the model was subject
to extensive debugging/veriﬁcation; and the model was calibrated
to local South Australian data before performing the model
analysis. We cross-validated the study by comparing and con-
trasting the outcomes of our discrete event simulation model
with those of an alternative, cohort-based state transition model
that was built to inform the same decision [11]. External vali-
dation of our model will occur as new evidence becomes
available.
A further strength of our study is the use of linked, longi-
tudinal individual-level data that represented the observed
follow-up mammography schedule received by each of the 407
patients. This approach precluded the secondary parameteriza-
tion of surveillance frequency, an important parameter that is
generally subject to signiﬁcant uncertainty. Taylor et al. [38]
illustrated the importance of reﬂecting actual surveillance, com-
paring the effect of conventional calibration (assume all women
had been exposed to current screening processes in the past) and
a historically accurate calibration that reﬂected the fact that US
women 65 years or older had not received currently available
screening practices for cervical cancer at younger ages. They
concluded that calibrating longitudinal models to cross-sectional
data without accounting for temporal changes in clinical practice
may lead to bias in evaluating the effectiveness of interventions
[38].
Our study does have several limitations. First, the quality and
quantity of the collected input and calibration target data placed
constraints on our intended analysis: the South Australian
Cancer Registry did not collect data on the hormone receptor
status of the primary breast cancer before June 2012, and data on
HER2 receptor status are not yet collected, which limits the
precision of our risk stratiﬁcation technique; our eligible popula-
tion was limited to patients receiving their primary treatment in
the public sector because privacy laws prevented access to
mammography and pathology reports from the private sector;
and because recurrence and follow-up data are not routinely
collected in South Australia, the need to link four separate data
sources (each built for different purposes) resulted in loss of data
because of an inability to match all patients across all databases.
Second, although prior probability functions were used to
reduce the parameter space searched as part of the calibration
process, guided, algorithmic search strategies are likely to have
improved the efﬁciency and accuracy of the process compared
with the applied random sampling approach [39,40].
Third, there is the potential to build more comprehensive
models that could include premenopausal women; additional
features of the primary tumor that have an impact on prognosis
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Fig. 2 – Cost-effectiveness acceptability curves for (A) 50- to 69-year-old cohort and (B) 70- to 79-year-old cohort.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 6 9 – 6 7 8676(e.g., receptor status); treatment regimens; and a range of alter-
native surveillance strategies that include other imaging modal-
ities (e.g., magnetic resonance imaging or ultrasound) as an
adjunct to mammography, imaging both with and without
clinical examination, and other frequencies of mammographic
surveillance. Our analysis does not represent clinical examina-
tion as an alternative or supplementary method of surveillance;
rather, the detection of a recurrent tumor by the patient or the
physician is reﬂected as an exogenous event. Without patient-
level data describing the timing and frequency of clinical exami-
nation, and the mode of detection of recurrent tumors, there was
too little data to inform such an extension to the model. To
inform this option would have required case note review for the
entire South Australian cohort over a 10-year period, which was
beyond the scope of this study.Fourth, the adherence scenarios represented independent
probabilities of adherence to each scheduled mammographic
attendance. In reality, adherence probabilities are likely to be
correlated across separate scheduled attendances for individuals.
The representation of such correlation would improve the cost-
effectiveness of the less frequent surveillance strategies because
the eligible population would tend toward a smaller group of
better-adhering individuals.
Our results suggest that mammographic follow-up can poten-
tially be tailored according to the risk of recurrence based on the
NPI score of the primary breast cancer and age at diagnosis. If our
current model is validated with a larger data set, this could
potentially provide the foundations toward a signiﬁcant change
in current imaging practice in breast cancer follow-up. The
model-based cost-effectiveness analysis could inform
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 6 9 – 6 7 8 677subsequent activities, including elicitation of patient preferences,
stakeholder engagement, and deliberations and research that
explicitly consider all salient social, ethical, political, legal,
economic, and clinical consequences [41] of tailored mammog-
raphy schedules.Conclusions
The reported analyses suggest that the current one-size-ﬁts-all
guideline of annual follow-up mammography for all women who
are disease free following the completion of primary treatment
for early breast cancer may not be cost-effective. Less frequent
mammographic surveillance may be more cost-effective for
postmenopausal women with moderate risk of recurrent breast
cancer, especially those older than 70 years.
Moreover, this study in breast cancer follow-up has demon-
strated the potential value of using linked, longitudinal,
individual-level data within a calibration-based decision-analytic
modeling framework to evaluate the cost-effectiveness of alter-
native surveillance interventions. Further effort may be required
to collect more complete data that are sufﬁciently robust to
inform policy and practice, but given the difﬁcultly in conducting
high-quality clinical studies, model-based analyses are of partic-
ular relevance to the evaluation of surveillance.
As better prognostic factors are identiﬁed across a wide range
of cancers, the potential beneﬁts of tailoring follow-up to the risk
of recurrence will increase and so we should be developing
analytic methods that will guide clinical practice not only in an
evidence-based but also pragmatic manner.Acknowledgments
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